Back

Development of S-1 in metastatic colorectal cancer (mCRC)

19 June 2026 (13:20 - 13:35)
Organised by: Logo
Congress Presentation Part of: Cardiovascular toxicity of fluoropyrimidines: Clinical challenges and emerging management strategies Cardiovascular Toxicity of Cancer Therapies Open Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Professor Cornelis Punt

Julius Health Center - Julius Gezondheidscentra, Utrecht (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Welcome and introduction
Doctor A. Lyon (London, GB)
Presentation thumbnail
Cardiovascular toxicity of fluoropyrimidines
Doctor A. Lyon (London, GB)
Slides
Presentation thumbnail
From science to clinical practice: treatment options following cardiovascular toxicity
Doctor I. Fabiani (Pisa, IT)
Slides
Presentation thumbnail
Discussion and Q&A
Slides

Access the full session

Session thumbnail
Cardiovascular toxicity of fluoropyrimidines: Clinical challenges and emerging management strategies
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 13:20 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of S-1-based treatment in colorectal cancer patients who switched to S-1 after development of cardiotoxicity on fluoropyrimidine-based adjuvant or neoadjuvant treatment
20 June 2025
thumbnail
Webinar
Cancer associated thrombosis: have DOACs changed daily practice?
21 September 2021
thumbnail
Congress Presentation
Cardio-oncology blitz registry offers real-world data in a gastrointestinal cancer population
21 June 2025
thumbnail
Congress Presentation
Statin therapy for the prevention of venous thromboembolism in cancer patients: a systematic review and meta-analysis
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources